Trailing-twelve-month (TTM) revenue is $11.47 Billion with a year-over-year growth of +5.36%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $2,835,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-31 | $2,974,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-12 |
| Q1 FY2026Period ended 2026-03-31 | $2,701,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-30 |
| Q2 FY2026Period ended 2026-06-30 | $2,960,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-30 |
| TTM revenue | $11,470,000,000 |
Current P/S: $12,609,532,245 market capitalization ÷ $11,470,000,000 TTM revenue = 1.10x.
Market capitalization source: FMP quote. Quote observed 2026-09-09T20:00:02.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $2.96B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-09T20:00:02.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Acute Therapies | $740M | $782M | $701M | N/A | N/A | N/A |
| Advanced Surgery | $888M | $1.0B | $1.3B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| EMEA | N/A | N/A | N/A | $3.3B | $1.4B | $1.4B |
| Non-US | $6.8B | $7.6B | $7.6B |
$11.47B
$11.47 Billion
+5.36%
vs. $10.89B a year ago (TTM)
(1.22%)
5 Year compound annual growth rate
1 Year
+5.36%
3 Year
(7.97%)
5 Year
(1.22%)
10 Year
+1.33%
15 Year
(1.10%)
20 Year
+0.71%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $11.24B | +$608.00M | +5.72% |
| 2024 | $10.64B | +$276.00M | +2.66% |
| 2023 | $10.36B | +$303.00M | +3.01% |
| 2022 | $10.06B | ($2.09B) | (17.20%) |
| 2021 | $12.15B | +$473.00M | +4.05% |
| 2020 |
TTM Growth
+5.36%
3-Year CAGR
(7.97%)
5-Year CAGR
(1.22%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-09T20:00:02.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| N/A |
| Clinical Nutrition | $922M | $964M | $931M | N/A | N/A | N/A |
|---|
| Front Line Care | N/A | $70M | $1.1B | N/A | N/A | N/A |
|---|
| Healthcare Systems and Technologies | N/A | N/A | N/A | $3.0B | $3.0B | $3.1B |
|---|
| Kidney Care | N/A | N/A | N/A | $4.5B | N/A | N/A |
|---|
| Medical Products And Therapies | N/A | N/A | N/A | $5.0B | $5.2B | $5.3B |
|---|
| Medication Delivery | $2.7B | $2.9B | $2.9B | N/A | N/A | N/A |
|---|
| Patient Support Systems | N/A | $115M | $1.5B | N/A | N/A | N/A |
|---|
| Pharmaceuticals | $2.1B | $2.3B | $2.1B | $2.2B | $2.4B | $2.5B |
|---|
| Renal | $3.8B | $3.9B | $3.7B | N/A | N/A | N/A |
|---|
| Surgical Solutions | N/A | $669M | $644M | N/A | N/A | N/A |
|---|
| N/A |
| N/A |
| UNITED STATES | $4.9B | $5.2B | $7.0B | $7.0B | $5.8B | $6.1B |
|---|
| Western Europe, Canada, Japan, Australia and New Zealand | N/A | N/A | N/A | $4.5B | $3.4B | $3.7B |
|---|
| $11.67B |
| +$311.00M |
| +2.74% |
| 2019 | $11.36B | +$263.00M | +2.37% |
| 2018 | $11.10B | +$515.00M | +4.87% |
| 2017 | $10.58B | +$421.00M | +4.14% |
| 2016 | $10.16B | +$195.00M | +1.96% |
